300 related articles for article (PubMed ID: 33815608)
1. Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review).
Volovat SR; Negru S; Stolniceanu CR; Volovat C; Lungulescu C; Scripcariu D; Cobzeanu BM; Stefanescu C; Grigorescu C; Augustin I; Lupascu Ursulescu C; Volovat CC
Exp Ther Med; 2021 May; 21(5):535. PubMed ID: 33815608
[TBL] [Abstract][Full Text] [Related]
2. Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.
Wang C; Ye Y; Hu Q; Bellotti A; Gu Z
Adv Mater; 2017 Aug; 29(29):. PubMed ID: 28556553
[TBL] [Abstract][Full Text] [Related]
3. Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects.
Farhana A
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834917
[TBL] [Abstract][Full Text] [Related]
4. Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.
Sadozai H; Gruber T; Hunger RE; Schenk M
Front Immunol; 2017; 8():1617. PubMed ID: 29276510
[TBL] [Abstract][Full Text] [Related]
5. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
6. Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia.
Wan Z; Sun R; Moharil P; Chen J; Liu Y; Song X; Ao Q
J Leukoc Biol; 2021 Feb; 109(2):425-436. PubMed ID: 33259068
[TBL] [Abstract][Full Text] [Related]
7. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine for Combination Urologic Cancer Immunotherapy.
Tian Y; Liu Z; Wang J; Li L; Wang F; Zhu Z; Wang X
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839868
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for cutaneous malignancy.
Ibrahim SF; Sambandan D; Ratner D
Dermatol Surg; 2011 Oct; 37(10):1377-93. PubMed ID: 21806705
[TBL] [Abstract][Full Text] [Related]
10. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
11. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine and macroscale materials in immuno-oncology.
Sun Q; Barz M; De Geest BG; Diken M; Hennink WE; Kiessling F; Lammers T; Shi Y
Chem Soc Rev; 2019 Jan; 48(1):351-381. PubMed ID: 30465669
[TBL] [Abstract][Full Text] [Related]
13. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
Rhodes KR; Green JJ
Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine-Combined Immunotherapy for Cancer.
Huang S; Zhao Q
Curr Med Chem; 2020; 27(34):5716-5729. PubMed ID: 31250752
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology platforms for cancer immunotherapy.
Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
[TBL] [Abstract][Full Text] [Related]
16. Biomaterial-assisted photoimmunotherapy for cancer.
Chen M; Chen Q
Biomater Sci; 2020 Nov; 8(21):5846-5858. PubMed ID: 33016276
[TBL] [Abstract][Full Text] [Related]
17. Bioengineering of nano metal-organic frameworks for cancer immunotherapy.
Chong G; Zang J; Han Y; Su R; Weeranoppanant N; Dong H; Li Y
Nano Res; 2021; 14(5):1244-1259. PubMed ID: 33250971
[TBL] [Abstract][Full Text] [Related]
18. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
20. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
